Pregabalin in restless legs syndrome with and without neuropathic pain

  title={Pregabalin in restless legs syndrome with and without neuropathic pain},
  author={Martin Sommer and Cornelius G. Bachmann and K M Liebetanz and Jan Schindehuette and Tobias Tings and Walter Paulus},
  journal={Acta Neurologica Scandinavica},
Background –  Restless legs syndrome (RLS) is a common neurological disorder complicated in many patients by augmentation to dopaminergic therapy or comorbidities such as neuropathic pain. 
Pregabalin is more effective than placebo for restless legs syndrome with mild adverse effects of daytime somnolence, headache and unsteadiness
Treatment of restless legs syndrome with pregabalin with a double-blind, placebo-controlled study and results show promising results.
Brazilian consensus on guidelines for diagnosis and treatment for restless legs syndrome.
The Consensus on restless legs syndrome is an effort of neurologists from several Brazilian states, which tirelessly reviewed the literature of recent years in search of evidence, both in regard to
Movement Disorders restless legs Syndrome Table 1 : Classification of Drugs Assayed for Treatment of Restless Legs Syndrome
Preliminary results suggest that several non-pharmacological therapies should be promising as alternatives or adjuvants to drug treatments and dopamine agonists, gabapentin and pregabalin should be considered as first-line therapies.
Restless legs syndrome: clinical presentation diagnosis and treatment.
Treatment of restless legs syndrome.
Restless legs syndrome: pathophysiology, clinical presentation and management
Iron deficiency must be identified and treated by supplementation, both to improve RLS symptoms and to potentially lower the risk of augmentation.
Long‐term management issues in restless legs syndrome
  • S. Chokroverty
  • Medicine, Psychology
    Movement disorders : official journal of the Movement Disorder Society
  • 2011
Several short‐term and some long‐term open‐label and double‐blind clinical trials have demonstrated the efficacy and safety of dopaminergic treatment in restless legs syndrome.
Update on the management of restless legs syndrome: existing and emerging treatment options
Dopaminergic agents are considered as the first-line therapy for moderate to severe RLS, and gabapentin or other antiepileptic agents, benzodiazepines, or opioids can be used for RLS therapy.
A Cost‐Consequences Analysis of the Effect of Pregabalin in the Treatment of Painful Radiculopathy under Medical Practice Conditions in Primary Care Settings
Purpose:  To analyze the effect of pregabalin (PGB) on pain relief, longitudinal utilization of health and nonhealth resources and derived costs in patients with refractory painful radiculopathy


Treatment of idiopathic restless legs syndrome (RLS) with gabapentin
It is concluded that gabapentin provides a well-tolerated and effective treatment of idiopathic restless legs syndrome.
Restless Legs Syndrome induced by impairment of sensory spinal pathways
This report presents for the first time a patient who developed symptoms of RLS following a persisting vascular lesion of sensory spinal pathways, and the patient made a nearly complete recovery of his sensory and motor deficits within half a year.
Restless legs syndrome
Patients with restless legs syndrome (RLS) should be evaluated for iron deficiency anemia; iron replacement in deficient patients may lead to a resolution of symptoms or may reduce the severity of their symptoms.
Augmentation of the restless legs syndrome with carbidopa/levodopa.
A previously unreported but far more significant problem of markedly augmented RL symptoms occurred in the afternoon and the evening prior to taking the next nightly dose, and this augmentation was severe enough to require medication change for 50% of the RL patients and 13% of PLMS patients.
Ropinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countries.
Ropinirole improves restless legs syndrome compared with placebo, with benefits apparent by week 1, and is generally well tolerated.
Restless legs syndrome prevalence and impact: REST general population study.
Clinically significant RLS is common (prevalence, 2.7%), is underdiagnosed, and significantly affects sleep and quality of life.
Complex segregation analysis of restless legs syndrome provides evidence for an autosomal dominant mode of inheritance in early age at onset families
The segregation pattern found in the authors' families argues for an autosomal allele acting dominantly in RLS families with an early age at onset of symptoms and suggests that RLS is a causative heterogeneous disease.